Publication at Faculty of Medicine in Pilsen |
2016
Abstract
Author presents actual informations on differences among adenocarcinomas and squamous cell carcinomas of the lung. Findings of driving mutations in tumour tissue is of value particularly in adenocarcinomas.
Targeted therapy by means of tyrosinkinase inhibitors should be given in patients with mutations of EGFR gene and translocations of genes EML-4 ALK and ROS1. Nowadays, there are at disposal targeted molecular tyrosinkinase inhibitors of higher generations to treat patients suffering from tumours resistant to targeted drugs of I.st. generation.